The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

被引：142

作者：

Wheeler, David C. ^{[1
]}

Stefansson, Bergur, V ^{[2
]}

Batiushin, Mikhail ^{[3
]}

Bilchenko, Oleksandr ^{[4
]}

Cherney, David Z., I ^{[5
,6
]}

Chertow, Glenn M. ^{[7
,8
]}

Douthat, Walter ^{[9
]}

Dwyer, Jamie P. ^{[10
]}

Escudero, Elizabeth ^{[11
]}

Pecoits-Filho, Roberto ^{[12
,13
]}

Furuland, Hans ^{[14
]}

Gorriz, Jose Luis ^{[15
]}

Greene, Tom ^{[16
]}

Haller, Hermann ^{[17
]}

Hou, Fan Fan ^{[18
]}

Kang, Shin-Wook ^{[19
]}

Isidto, Rey ^{[20
]}

Khullar, Dinesh ^{[21
]}

Mark, Patrick B. ^{[22
]}

McMurray, John J., V ^{[22
]}

Kashihara, Naoki ^{[23
]}

Nowicki, Michal ^{[24
]}

Persson, Frederik ^{[25
]}

Correa-Rotter, Ricardo ^{[26
]}

Rossing, Peter ^{[25
,27
]}

Toto, Robert D. ^{[28
]}

Umanath, Kausik ^{[29
,30
]}

Van Bui, Pham ^{[31
]}

Wittmann, Istvan ^{[32
,33
]}

Lindberg, Magnus ^{[2
]}

Sjostrom, C. David ^{[2
]}

Langkilde, Anna Maria ^{[2
]}

Heerspink, Hiddo J. L. ^{[34
]}

机构：

[1] UCL, Dept Renal Med, London, England

[2] AstraZeneca, BioPharmaceut R&D, Late Stage Dev Cardiovasc Renal & Metab, Gothenburg, Sweden

[3] Rostov State Med Univ, Dept Nephrol, Rostov Na Donu, Russia

[4] Kharkiv Med Acad Postgrad Educ, Kharkiv, Ukraine

[5] Univ Hlth Network, Toronto Gen Hosp Res Inst, Toronto, ON, Canada

[6] Univ Toronto, Dept Med, Div Nephrol, Toronto, ON, Canada

[7] Stanford Univ, Dept Epidemiol & Populat Hlth, Sch Med, Stanford, CA USA

[8] Stanford Univ, Dept Med, Sch Med, Stanford, CA USA

[9] Hosp Privado Univ Cordoba, Dept Nephrol, Cordoba, Argentina

[10] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[11] Cayetano Heredia Univ, Hosp Arzobispo Loayza, Div Nephrol, Lima, Peru

[12] Pontificia Univ Catolica Parana, Sch Med, Curitiba, Parana, Brazil

[13] Arbor Res Collaborat Hlth, Ann Arbor, MI USA

[14] Uppsala Univ Hosp, Dept Med Sci Renal Unit, Uppsala, Sweden

[15] Univ Valencia, Univ Clin Hosp, Dept Nephrol, INCLIVA, Valencia, Spain

[16] Univ Utah Hlth Sci, Study Design & Biostat Ctr, Salt Lake City, UT USA

[17] Hannover Med Sch, Hannover, Germany

[18] Southern Med Univ, Natl Clin Res Ctr Kidney Dis, Dept Med, Div Nephrol, Guangzhou, Peoples R China

[19] Yonsei Univ, Dept Internal Med, Div Nephrol, Coll Med, Seoul, South Korea

[20] Healthlink Med Dent Surg Clin & Diagnost Ctr, Iloilo, Philippines

[21] Max Super Special Hosp, Dept Nephrol & Renal Transplant Med, New Delhi, India

[22] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland

[23] Kawasaki Med Sch, Dept Nephrol & Hypertens, Okayama, Japan

[24] Med Univ Lodz, Dept Nephrol Hypertens & Kidney Transplantat, Lodz, Poland

[25] Steno Diabet Ctr Copenhagen, Gentofte, Denmark

[26] Natl Med Sci & Nutr Inst Salvador Zubiran, Mexico City, DF, Mexico

[27] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark

[28] UT Southwestern Med Ctr, Dept Internal Med, Dallas, TX USA

[29] Henry Ford Hosp, Div Nephrol & Hypertens, Detroit, MI 48202 USA

[30] Wayne State Univ, Div Nephrol & Hypertens, Detroit, MI USA

[31] Pham Ngoc Thach Med Univ, Ho Chi Minh City, Vietnam

[32] Univ Pecs, Dept Med 2, Med Sch, Pecs, Hungary

[33] Univ Pecs, Nephrol Diabet Ctr, Med Sch, Pecs, Hungary

[34] Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 2020年 / 35卷 / 10期

关键词：

chronic kidney disease; dapagliflozin; randomized controlled clinical trial; sodium-glucose co-transporter-2 inhibitor; IGA NEPHROPATHY; END-POINTS; RATIONALE; FAILURE; PROGRESSION; INHIBITION; BENAZEPRIL; EFFICACY; DECLINE; DESIGN;

D O I：

10.1093/ndt/gfaa234

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

Background. The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on kidney and cardiovascular events in participants with CKD with and without type 2 diabetes (T2D). This analysis reports the baseline characteristics of those recruited, comparing them with those enrolled in other trials. Methods. In DAPA-CKD, 4304 participants with a urinary albumin:creatinine ratio (UACR) <= 200mg/g and estimated glomerular filtration rate (eGFR) between 25 and 75mL/min/1.73m(2) were randomized to dapagliflozin 10mg once daily or placebo. Mean eGFR was 43.1mL/min/1.73m(2) and median UACR was 949 mg/g (108mg/mmol). Results. Overall, 2906 participants (68%) had a diagnosis of T2D and of these, 396 had CKD ascribed to a cause other than diabetes. The most common causes of CKD after diabetes (n = 2510) were ischaemic/hypertensive nephropathy (n = 687) and chronic glomerulonephritis (n = 695), of which immunoglobulin A nephropathy (n = 270) was the most common. A total of 4174 participants (97%) were receiving an angiotensinconverting enzyme inhibitor or angiotensin receptor blocker, 1882 (43.7%) diuretics, 229 (5.3%) mineralocorticoid receptor antagonists and 122 (2.8%) glucagon-like peptide 1 receptor agonists. In contrast to the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), the DAPA-CKD trial enrolled participants with CKD due to diabetes and to causes other than diabetes. The mean eGFR of participants in the DAPA-CKD trial was 13.1mL/min/1.73m(2) lower than in CREDENCE, similar to that in the Finerenone in Reducing Kidney Failure and Disease Progression in DKD (FIDELIO-DKD) trial and the Study Of diabetic Nephropathy with AtRasentan (SONAR). Conclusions. Participants with a wide range of underlying kidney diseases receiving renin-angiotensin system blocking therapy have been enrolled in the DAPA-CKD trial. The trial will examine the efficacy and safety of dapagliflozin in participants with CKD Stages 2-4 and increased albuminuria, with and without T2D.

引用

页码：1700 / 1711

页数：12

共 28 条

[1]

[Anonymous], 2020, BAYERS FINERENONE ME

[2]

AstraZeneca, 2020, FARX PHAS 3 DAP CKD

[3] Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial [J].

Bakris, George L. ;

Agarwal, Rajiv ;

Anker, Stefan D. ;

Pitt, Bertram ;

Ruilope, Luis M. ;

Nowack, Christina ;

Kolkhof, Peter ;

Ferreira, Anna C. ;

Schloemer, Patrick ;

Filippatos, Gerasimos .

AMERICAN JOURNAL OF NEPHROLOGY, 2019, 50 (05) :333-344

[4] Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial) [J].

Barratt, Jonathan ;

Rovin, Brad ;

Diva, Ulysses ;

Mercer, Alex ;

Komers, Radko .

KIDNEY INTERNATIONAL REPORTS, 2019, 4 (11) :1633-1637

[5]

Cherney DZI, 2020, LANCET DIABETES ENDO, V8, P582, DOI 10.1016/S2213-8587(20)30162-5

[6] Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus [J].

Cherney, David Z. I. ;

Perkins, Bruce A. ;

Soleymanlou, Nima ;

Maione, Maria ;

Lai, Vesta ;

Lee, Alana ;

Fagan, Nora M. ;

Woerle, Hans J. ;

Johansen, Odd Erik ;

Broedl, Uli C. ;

von Eynatten, Maximilian .

CIRCULATION, 2014, 129 (05) :587-597

[7] Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial [J].

Heerspink, Hiddo J. L. ;

Stefansson, Bergur, V ;

Chertow, Glenn M. ;

Correa-Rotter, Ricardo ;

Greene, Tom ;

Hou, Fan-Fan ;

Lindberg, Magnus ;

McMurray, John ;

Rossing, Peter ;

Toto, Roberto ;

Langkilde, Anna Maria ;

Wheeler, David C. .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 (02) :274-282

[8] Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial [J].

Heerspink, Hiddo J. L. ;

Parving, Hans-Henrik ;

Andress, Dennis L. ;

Bakris, George ;

Correa-Rotter, Ricardo ;

Hou, Fan-Fan ;

Kitzman, Dalane W. ;

Kohan, Donald ;

Makino, Hirofumi ;

McMurray, John J. V. ;

Melnick, Joel Z. ;

Miller, Michael G. ;

Pergola, Pablo E. ;

Perkovic, Vlado ;

Tobe, Sheldon ;

Yi, Tingting ;

Wigderson, Melissa ;

de Zeeuw, Dick .

LANCET, 2019, 393 (10184) :1937-1947

[9] Baseline characteristics and enrichment results from the SONAR trial [J].

Heerspink, Hiddo J. L. ;

Andress, Dennis L. ;

Bakris, George ;

Brennan, John J. ;

Correa-Rotter, Ricardo ;

Hou, Fan Fan ;

Kitzman, Dalane W. ;

Kohan, Donald ;

Makino, Hirofumi ;

McMurray, John ;

Perkovic, Vlado ;

Tobe, Sheldon ;

Wigderson, Melissa ;

Yi, Tingting ;

Parving, Hans-Henrik ;

de Zeeuw, Dick .

DIABETES OBESITY & METABOLISM, 2018, 20 (08) :1829-1835

[10] Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy [J].

Heerspink, Hiddo J. L. ;

Andress, Dennis L. ;

Bakris, George ;

Brennan, John J. ;

Correa-Rotter, Ricardo ;

Dey, Jyotirmoy ;

Hou, Fan Fan ;

Kitzman, Dalane W. ;

Kohan, Donald ;

Makino, Hirofumi ;

McMurray, John ;

Perkovic, Vlado ;

Tobe, Sheldon ;

Wigderson, Melissa ;

Parving, Hans-Henrik ;

de Zeeuw, Dick .

DIABETES OBESITY & METABOLISM, 2018, 20 (06) :1369-1376

← 1 2 3 →